Sylvie Deuffic-Burban

Summary

Country: France

Publications

  1. ncbi Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model
    S Deuffic-Burban
    Unité de Recherche Epidémiologie et Sciences de l Information, INSERM U444, CHU Sanit Antoine, 27 rue Chaligny, 75012 Paris, France
    J Viral Hepat 9:114-22. 2002
  2. ncbi Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness
    Laurence Bocket
    Virology Department, Centre Hospitalier Universitaire de Lille, France
    Antivir Ther 10:247-54. 2005
  3. ncbi The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire
    Elena Losina
    Department of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, MA, USA
    Antivir Ther 12:543-51. 2007
  4. ncbi Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling
    Sylvie Deuffic-Burban
    CTRS, Unité INSERM 795, Hôpital Swynghedauw, CHRU de Lille, Lille, France
    Eur J Epidemiol 22:737-44. 2007
  5. ncbi Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States
    S Deuffic-Burban
    CRESGE LEM, CNRS UMR 8179, Lille, France
    J Viral Hepat 14:107-15. 2007
  6. ncbi Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000
    Sylvie Deuffic-Burban
    CRESGE LEM, CNRS UMR 8179, Lille, France
    Eur J Epidemiol 21:389-96. 2006
  7. ncbi Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections
    Sylvie Deuffic-Burban
    CRESGE LABORES, CNRS URA 362, 1 rue Norbert Ségard, BP 109, 59016 Lille, France
    J Hepatol 44:455-61. 2006
  8. ncbi Comparing the public health burden of chronic hepatitis C and HIV infection in France
    Sylvie Deuffic-Burban
    Unité de Recherche Epidémiologie et Sciences de l Information INSERM U444, Faculte de Medecine Saint Antoine, 27 rue Chaligny, 75 571 Paris Cedex 12, France
    J Hepatol 40:319-26. 2004
  9. ncbi Predicted effects of treatment for HCV infection vary among European countries
    Sylvie Deuffic-Burban
    ATIP AVENIR INSERM Unité 995, Lille, France
    Gastroenterology 143:974-85.e14. 2012
  10. ncbi Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis
    Sylvie Deuffic-Burban
    ATIP AVENIR Inserm U995, Universite Lille Nord de France, Lille, France
    Gut 61:290-6. 2012

Detail Information

Publications18

  1. ncbi Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model
    S Deuffic-Burban
    Unité de Recherche Epidémiologie et Sciences de l Information, INSERM U444, CHU Sanit Antoine, 27 rue Chaligny, 75012 Paris, France
    J Viral Hepat 9:114-22. 2002
    ..Hence Markov modelling is an accurate tool in the analysis of fibrosis progression in chronic hepatitis C. It will be valuable for the quantification of the effect of new treatments on fibrosis progression in hepatitis C...
  2. ncbi Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness
    Laurence Bocket
    Virology Department, Centre Hospitalier Universitaire de Lille, France
    Antivir Ther 10:247-54. 2005
    ..The effectiveness of antiretroviral treatment (ART) was compared in 416 naive patients from a French clinical cohort infected with B and non-B HIV-1 subtypes...
  3. ncbi The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire
    Elena Losina
    Department of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, MA, USA
    Antivir Ther 12:543-51. 2007
    ..Studies in developed countries have shown highly active antiretroviral therapy (HAART) decreases incidence of severe opportunistic diseases (ODs) in HIV-infected patients beyond that which is expected from changes in CD4+ T-cell count...
  4. ncbi Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling
    Sylvie Deuffic-Burban
    CTRS, Unité INSERM 795, Hôpital Swynghedauw, CHRU de Lille, Lille, France
    Eur J Epidemiol 22:737-44. 2007
    ..All of the models indicate that the overall incidence of opportunistic infections under HAART in sub-Saharan Africa is high. This suggests that prophylaxis against opportunistic infections may be needed even for patients receiving HAART...
  5. ncbi Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States
    S Deuffic-Burban
    CRESGE LEM, CNRS UMR 8179, Lille, France
    J Viral Hepat 14:107-15. 2007
    ....
  6. ncbi Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000
    Sylvie Deuffic-Burban
    CRESGE LEM, CNRS UMR 8179, Lille, France
    Eur J Epidemiol 21:389-96. 2006
    ..Taking into account pre-AIDS mortality of HIV-infected person in the back-calculation model increased the estimated HIV prevalence...
  7. ncbi Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections
    Sylvie Deuffic-Burban
    CRESGE LABORES, CNRS URA 362, 1 rue Norbert Ségard, BP 109, 59016 Lille, France
    J Hepatol 44:455-61. 2006
    ..Estimating the future burden of HCV in Egypt is important to support health policies to combat the epidemic...
  8. ncbi Comparing the public health burden of chronic hepatitis C and HIV infection in France
    Sylvie Deuffic-Burban
    Unité de Recherche Epidémiologie et Sciences de l Information INSERM U444, Faculte de Medecine Saint Antoine, 27 rue Chaligny, 75 571 Paris Cedex 12, France
    J Hepatol 40:319-26. 2004
    ..Using reported public health data in France and natural history models, we applied the back-calculation method to project future mortality from HCV and HIV incorporating current therapies...
  9. ncbi Predicted effects of treatment for HCV infection vary among European countries
    Sylvie Deuffic-Burban
    ATIP AVENIR INSERM Unité 995, Lille, France
    Gastroenterology 143:974-85.e14. 2012
    ..We also assessed the effects of treatment with pegylated interferon and additional effects of triple therapy with protease inhibitors...
  10. ncbi Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis
    Sylvie Deuffic-Burban
    ATIP AVENIR Inserm U995, Universite Lille Nord de France, Lille, France
    Gut 61:290-6. 2012
    ..The aim of this study was to estimate the number of G1 patients to be treated in France in 2012 and associated costs...
  11. ncbi Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France
    Sylvie Deuffic-Burban
    Institut National de la Santé et de la Recherche Médicale U795, Faculte de Medecine, Pole Recherche, Lille, France
    Hepatology 50:1351-9. 2009
    ..CONCLUSION: Treatment of N-ALT patients would decrease HCV morbidity and mortality. These patients should be considered candidates for treatment just as others are...
  12. ncbi Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France
    Sylvie Deuffic-Burban
    CTRS INSERM U795, CHRU Lille, Lille, France
    J Hepatol 49:175-83. 2008
    ..In France, two recent studies enabled modeling of the impact of viral eradication on HCV mortality...
  13. ncbi Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms
    Karen Champenois
    CRESGE LEM CNRS, Lille, France
    AIDS 22:1087-9. 2008
    ....
  14. ncbi Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis
    Sylvie Deuffic-Burban
    Inserm ATIP AVENIR Modélisation, aide à la décision et coût efficacité en maladies infectieuses, Lille Paris, France
    J Hepatol 57:260-6. 2012
    ....
  15. ncbi Modelling the past, current and future HCV burden in France: detailed analysis and perspectives
    Sylvie Deuffic-Burban
    CTRS INSERM U795, CHRU Lille, Lille, France
    Stat Methods Med Res 18:233-52. 2009
    ..The models offered a useful tool to assess public health policy scenarios in planning healthcare responses to the HCV epidemic...
  16. ncbi Age and gender will survive to competing risks as fibrosis factors
    Thierry Poynard
    Gastroenterology 128:519-20; author reply 520-1. 2005
  17. ncbi Hyperlactataemia during antiretroviral therapy: incidences, clinical data and treatment
    Yann Gerard
    Service Regional Universitaire des Maladies Infectieuses et du Voyageur, Hôpital Dron, Tourcoing, France
    Therapie 58:153-8. 2003
    ..The early diagnosis of cases was the result of great vigilance and, combined with routine measurements of the anion gap, might be the most crucial factor explaining the low mortality rate observed here...
  18. ncbi Natural polymorphisms in HIV-1 protease: impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen
    Karen Champenois
    Tourcoing AIDS reference centre, France
    J Med Virol 80:1871-9. 2008
    ..However, polymorphisms may affect ART effectiveness differently in other populations, such as ART-experienced patients and/or patients treated with protease inhibitors other than the one used here...